Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment

MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1

“…Annually, EOC caused estimated 125,000 deaths worldwide [2]. Due to the lack of definitive early symptoms and efficient diagnostic markers, the majority of EOC patients are diagnosed at the advance stage of the disease, which typically has a 5-year survival less than 30% [3].…”

Follow-Up of Patients Who Are Clinically Disease-Free after Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation

“…Regarding other methods of detection, physical examination has low sensitivity 16,28,32 , and ultrasonography has not been shown to be more useful than a combination of ca125 testing and clinical examination 8 . Computed tomography and magnetic resonance imaging have a role in treatment planning when a recurrence has been diagnosed; the roles of positron-emission tomography and Doppler ultrasonography are currently unclear 8 .…”

“…Computed tomography and magnetic resonance imaging have a role in treatment planning when a recurrence has been diagnosed; the roles of positron-emission tomography and Doppler ultrasonography are currently unclear 8 .…”

“…Evidence from follow-up of vulvar, cervical, and endometrial cancers has called into question the value of detecting asymptomatic recurrences, and follow-up has even been shown to delay detection, because some women will not report symptoms until their next scheduled appointment 7 . In the case of cancer in other disease sites (such as the bowel), intensive follow-up does appear to provide a benefit over little or no follow-up 8 .…”

The future for follow-up of gynaecological cancer in Europe. Summary of available data and overview of ongoing trials

“…A review by Piovano et al (2014) looking at HE4 currently has no recommendation regarding its incorporation into clinical practice [42] although elevated levels may be more sensitive at detecting relapse then serum CA125 [43]. The use of other tumour markers such as CEA and routine imaging have not been recommended for asymptomatic women from a Cochrane review of ovarian cancer follow-up [44]. Furthermore, this systematic review reported on only one RCT.…”